Targeting the Toughest Diseases looks at some of humanity’s most challenging diseases and how Vertex Pharmaceuticals, a Boston-based biotech company, is using innovative tools, methods, and a unique philosophy to search for treatments and cures. Produced by Bloomberg Media Studios and Vertex Pharmaceuticals.
All content for Targeting the Toughest Diseases is the property of Vertex Pharmaceuticals and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Targeting the Toughest Diseases looks at some of humanity’s most challenging diseases and how Vertex Pharmaceuticals, a Boston-based biotech company, is using innovative tools, methods, and a unique philosophy to search for treatments and cures. Produced by Bloomberg Media Studios and Vertex Pharmaceuticals.
John Killian’s son was diagnosed with Duchenne muscular dystrophy (DMD) as a toddler. Until recently, children with DMD were not expected to live beyond their teens. The disease weakens the body's muscles and cognitive functions, which can lead to premature death. John’s son is now college-bound, thanks to the help of medical advancements that target the symptoms of the disease. Geneticist Dr. Alison McVie-Wylie and the research team at Vertex hope to move past only treating the symptoms of DMD by addressing the disease at its root cause.
Produced by Bloomberg Media Studios and Vertex Pharmaceuticals.
Targeting the Toughest Diseases
Targeting the Toughest Diseases looks at some of humanity’s most challenging diseases and how Vertex Pharmaceuticals, a Boston-based biotech company, is using innovative tools, methods, and a unique philosophy to search for treatments and cures. Produced by Bloomberg Media Studios and Vertex Pharmaceuticals.
